Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

A new generative AI tool developed by Mass General Brigham researchers, called RECTIFIER, was more efficient at screening and enrolling patients for a heart failure clinical trial than manual ...

The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results ... The most common adverse reactions (≥ 10%, all Grades), including laboratory abnormalities, for patients in the ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

TACTIVE-K: Phase 1b/2 clinical trial with vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

These restrictions have raised concerns, particularly within the defence sector. Tungsten, a key material for munitions, is among the metals targeted by China. “They could put some significant harm on ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...